QRG Capital Management Inc. Acquires New Position in BioNTech SE Sponsored ADR $BNTX

QRG Capital Management Inc. acquired a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,963 shares of the company’s stock, valued at approximately $489,000.

Several other large investors have also recently modified their holdings of BNTX. Rhenman & Partners Asset Management AB lifted its stake in shares of BioNTech by 0.3% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock valued at $3,819,000 after buying an additional 120 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of BioNTech by 0.8% during the second quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock worth $1,748,000 after acquiring an additional 127 shares in the last quarter. Profund Advisors LLC boosted its holdings in shares of BioNTech by 3.6% in the second quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock worth $459,000 after acquiring an additional 149 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. grew its position in shares of BioNTech by 2.5% in the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,653 shares of the company’s stock valued at $822,000 after purchasing an additional 186 shares in the last quarter. Finally, SBI Securities Co. Ltd. raised its stake in shares of BioNTech by 5.2% during the 2nd quarter. SBI Securities Co. Ltd. now owns 3,865 shares of the company’s stock valued at $412,000 after purchasing an additional 192 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Price Performance

BNTX opened at $118.47 on Friday. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $26.68 billion, a P/E ratio of -45.05 and a beta of 1.40. The stock has a 50-day moving average price of $99.14 and a 200-day moving average price of $103.69. BioNTech SE Sponsored ADR has a 12-month low of $81.20 and a 12-month high of $126.77.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The firm had revenue of $1.78 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter in the previous year, the firm earned $0.81 EPS. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. Equities analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Morgan Stanley reaffirmed an “overweight” rating and set a $134.00 target price on shares of BioNTech in a report on Monday, November 3rd. TD Cowen reaffirmed a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Bank of America cut their price target on shares of BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a report on Wednesday, October 22nd. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and upped their price target for the stock from $115.00 to $142.00 in a report on Friday, January 16th. Finally, HC Wainwright restated a “buy” rating and set a $140.00 target price on shares of BioNTech in a research report on Thursday, December 11th. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $140.03.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.